Characterization of cloned human somatostatin receptor SSTR5

AM O'Carroll, K Raynor, SJ Lolait and T Reisine

Laboratory of Cell Biology, National Institute of Mental Health, Bethesda, Maryland 20892.

The recent molecular cloning of the genes encoding six distinct somatostatin (SRIF) receptor subtypes from various species has allowed for the individual expression and characterization of these receptors in mammalian cells. In the present study, we have cloned the human homologue of the SRIF receptor subtype SSTR5 (formerly termed SSTR4) and characterized its pharmacological and functional properties, as well as its distribution. Although there is 80.5% sequence homology between the cloned rat and human SSTR5 receptors, their pharmacological profiles differ. We have labeled both rat and human SSTR5, expressed in Chinese hamster ovary (CHO-K1) cells, with 125I-Tyr11-SRIF and performed inhibition studies using SRIF analogues of differing structures, including cyclic penta-, hexa-, and octapeptide SRIF analogues. Whereas rat SSTR5 bound compounds in all structural classes with high to moderate affinities, human SSTR5 bound most SRIF analogues with much lower affinity, with the exceptions of SRIF, SRIF-28, and L- 362,855. Like rat SSTR5, human SSTR5 mediated the inhibition by SRIF of forskolin-stimulated cAMP accumulation. However, the clinically used SRIF analogue SMS 201-995, which potently inhibited cAMP formation via interaction with rat SSTR5, did not inhibit cAMP accumulation in cells expressing human SSTR5. The distribution of expression of human SSTR5 mRNA, as analyzed by reverse transcription-polymerase chain reaction, shows selective expression in small intestine, heart, adrenal, cerebellum, pituitary, placenta, and skeletal muscle but not in kidney, liver, pancreas, uterus, thymus, testis, spleen, lung, thyroid, ovary, or mammary gland. The structural differences between cloned rat and human SSTR5 receptors suggest useful strategies for identifying regions of this receptor subtype that may be involved in ligand binding specificities. Identification of subtype-selective SRIF analogues may lead to more specific pharmacological therapeutic interventions.

Volume 46, Issue 2, pp. 291-298, 08/01/1994
Copyright © 1994 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				S.-K. Chen, G. Y.-P. Ko, and S. E. Dryer Somatostatin Peptides Produce Multiple Effects on Gating Properties of Native Cone Photoreceptor cGMP-Gated Channels That Depend on Circadian Phase and Previous Illumination J. Neurosci., November 7, 2007; 27(45): 12168 - 12175. [Abstract] [Full Text] [PDF]

				S. J. Lolait, L. Q. Stewart, D. S. Jessop, W. S. Young 3rd, and A.-M. O'Carroll The Hypothalamic-Pituitary-Adrenal Axis Response to Stress in Mice Lacking Functional Vasopressin V1b Receptors Endocrinology, February 1, 2007; 148(2): 849 - 856. [Abstract] [Full Text] [PDF]

				M. Duran-Prado, C. Bucharles, B. J. Gonzalez, R. Vazquez-Martinez, A. J. Martinez-Fuentes, S. Garcia-Navarro, S. J. Rhodes, H. Vaudry, M. M. Malagon, and J. P. Castano Porcine Somatostatin Receptor 2 Displays Typical Pharmacological sst2 Features but Unique Dynamics of Homodimerization and Internalization Endocrinology, January 1, 2007; 148(1): 411 - 421. [Abstract] [Full Text] [PDF]

				W. H T Smith, R U. Nair, D. Adamson, M. T Kearney, S. G Ball, and A. J Balmforth Somatostatin receptor subtype expression in the human heart: differential expression by myocytes and fibroblasts J. Endocrinol., December 1, 2005; 187(3): 379 - 386. [Abstract] [Full Text] [PDF]

				M. Grant, R. C. Patel, and U. Kumar The Role of Subtype-specific Ligand Binding and the C-tail Domain in Dimer Formation of Human Somatostatin Receptors J. Biol. Chem., September 10, 2004; 279(37): 38636 - 38643. [Abstract] [Full Text] [PDF]

				R. D. Murray, K. Kim, S.-G. Ren, I. Lewis, G. Weckbecker, C. Bruns, and S. Melmed The Novel Somatostatin Ligand (SOM230) Regulates Human and Rat Anterior Pituitary Hormone Secretion J. Clin. Endocrinol. Metab., June 1, 2004; 89(6): 3027 - 3032. [Abstract] [Full Text] [PDF]

				S. Petersenn, A. C. Rasch, C. Bohnke, and H. M. Schulte Identification of an Upstream Pituitary-Active Promoter of Human Somatostatin Receptor Subtype 5 Endocrinology, July 1, 2002; 143(7): 2626 - 2634. [Abstract] [Full Text] [PDF]

				V. Martínez, J. Rivier, D. Coy, and Y. Taché Intracisternal Injection of Somatostatin Receptor 5-Preferring Agonists Induces a Vagal Cholinergic Stimulation of Gastric Emptying in Rats J. Pharmacol. Exp. Ther., June 1, 2000; 293(3): 1099 - 1105. [Abstract] [Full Text]

				N. Baou, M. Bouras, J.-P. Droz, M. Benahmed, and S. Krantic Evidence for a selective loss of somatostatin receptor subtype expression in male germ cell tumors of seminoma type Carcinogenesis, April 1, 2000; 21(4): 805 - 810. [Abstract] [Full Text] [PDF]

				M. A. Sheridan, J. D. Kittilson, and B. J. Slagter Structure-Function Relationships of the Signaling System for the Somatostatin Peptide Hormone Family Integr. Comp. Biol., April 1, 2000; 40(2): 269 - 286. [Abstract] [Full Text] [PDF]

				T. J. Gillespie, A. Erenberg, S. Kim, J. Dong, J. E. Taylor, V. Hau, and T. P. Davis Novel Somatostatin Analogs for the Treatment of Acromegaly and Cancer Exhibit Improved In Vivo Stability and Distribution J. Pharmacol. Exp. Ther., April 1, 1998; 285(1): 95 - 104. [Abstract] [Full Text]

				N. Kimura, S. Tomizawa, K. N. Arai, and N. Kimura Chronic Treatment with Estrogen Up-Regulates Expression of sst2 Messenger Ribonucleic Acid (mRNA) but Down-Regulates Expression of sst5 mRNA in Rat Pituitaries Endocrinology, April 1, 1998; 139(4): 1573 - 1580. [Abstract] [Full Text] [PDF]

				P. Cordelier, J.-P. Esteve, C. Bousquet, N. Delesque, A.-M. O'Carroll, A. V. Schally, N. Vaysse, C. Susini, and L. Buscail Characterization of the antiproliferative signal mediated by the somatostatin receptor subtype sst5 PNAS, August 19, 1997; 94(17): 9343 - 9348. [Abstract] [Full Text] [PDF]

				L. Gnessi, A. Fabbri, and G. Spera Gonadal Peptides as Mediators of Development and Functional Control of the Testis: An Integrated System with Hormones and Local Environment Endocr. Rev., August 1, 1997; 18(4): 541 - 609. [Abstract] [Full Text] [PDF]

				A. A. Sinisi, A. Bellastella, D. Prezioso, M. R. Nicchio, T. Lotti, M. Salvatore, and D. Pasquali Different Expression Patterns of Somatostatin Receptor Subtypes in Cultured Epithelial Cells from Human Normal Prostate and Prostate Cancer J. Clin. Endocrinol. Metab., August 1, 1997; 82(8): 2566 - 2569. [Abstract] [Full Text] [PDF]

				A. J. Williams, A. D. Michel, W. Feniuk, and P. P. A. Humphrey Somatostatin5 Receptor-Mediated [35S]Guanosine-5'-O-(3-thio)triphosphate Binding: Agonist Potencies and the Influence of Sodium Chloride on Intrinsic Activity Mol. Pharmacol., June 1, 1997; 51(6): 1060 - 1069. [Abstract] [Full Text]

				R. A. James, V. D. Sarapura, C. Bruns, F. Raulf, J. M. Dowding, D. F. Gordon, W. M. Wood, and E. C. Ridgway Thyroid Hormone-Induced Expression of Specific Somatostatin Receptor Subtypes Correlates with Involution of the TtT-97 Murine Thyrotrope Tumor Endocrinology, February 1, 1997; 138(2): 719 - 724. [Abstract] [Full Text] [PDF]

				S. W.J. Lamberts, A.-J. van der Lely, W. W. de Herder, and L. J. Hofland Octreotide N. Engl. J. Med., January 25, 1996; 334(4): 246 - 254. [Full Text] [PDF]

				M. G. Eason and S. B. Liggett Identification of a G(s) Coupling Domain in the Amino Terminus of the Third Intracellular Loop of the alpha[IMAGE]-Adrenergic Receptor J. Biol. Chem., October 20, 1995; 270(42): 24753 - 24760. [Abstract] [Full Text] [PDF]